CRISPR THERAPEUTICS AG's ticker is CRSP and the CUSIP is H17182108. A total of 471 filers reported holding CRISPR THERAPEUTICS AG in Q3 2021. The put-call ratio across all filers is 1.71 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $3,458 | +23.2% | 76,178 | +52.4% | 0.24% | +29.3% |
| Q2 2023 | $2,807 | +228.3% | 49,998 | +164.5% | 0.18% | +211.9% |
| Q1 2023 | $855 | -99.6% | 18,904 | +512.8% | 0.06% | +268.8% |
| Q3 2022 | $202,000 | -31.3% | 3,085 | -34.1% | 0.02% | -11.1% |
| Q1 2022 | $294,000 | +35.5% | 4,680 | +63.4% | 0.02% | +50.0% |
| Q4 2021 | $217,000 | -28.1% | 2,865 | +6.1% | 0.01% | -33.3% |
| Q3 2021 | $302,000 | -28.4% | 2,700 | +3.6% | 0.02% | -30.8% |
| Q2 2021 | $422,000 | +40.7% | 2,605 | +5.9% | 0.03% | +30.0% |
| Q1 2021 | $300,000 | -19.8% | 2,460 | +0.8% | 0.02% | -23.1% |
| Q4 2020 | $374,000 | +79.8% | 2,440 | -2.0% | 0.03% | +62.5% |
| Q3 2020 | $208,000 | – | 2,490 | – | 0.02% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Versant Venture Management, LLC | 498,558 | $31,294,000 | 31.24% |
| NEA Management Company, LLC | 1,590,002 | $365,593,000 | 10.56% |
| Ariose Capital Management Ltd | 37,900 | $2,379,000 | 9.30% |
| ARK Investment Management | 9,404,071 | $590,294,000 | 2.46% |
| NIA IMPACT ADVISORS, LLC | 80,082 | $5,027,000 | 2.44% |
| Nikko Asset Management Americas, Inc. | 4,619,747 | $291,044,000 | 2.14% |
| PLUSTICK MANAGEMENT LLC | 50,000 | $3,139,000 | 1.98% |
| Integral Health Asset Management, LLC | 120,000 | $7,532,000 | 1.96% |
| Valiant Capital Management, L.P. | 240,683 | $15,108,000 | 1.73% |
| Deuterium Capital Management, LLC | 18,000 | $1,130,000 | 1.45% |